🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Yatharth Hospital & Trauma Care Services Limited YATHARTH NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.yatharthhospitals.com
Company Profile ↓
₹991.10
+39.60% 1Y
Mkt Cap₹9,549.68 Cr
P/E67.33
P/B4.71
52W High₹1,001.90
52W Low₹550.47
Book Value₹184.79
EPS (TTM)₹14.72

Company Overview

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 38.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 32.4% CAGR over the past five years.

Healthy Margins

Operating margin of 16.9% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

  • Mar 2026 Revenue of ₹1,207.17 Cr (+36.3% YoY); net profit ₹175.38 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +36.3%, earnings +34.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 32.4%, profit CAGR 38.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:32.39%
1 Year:36.31%

Compounded Profit Growth

5 Years:38.67%
1 Year:34.34%

Stock Price Performance

1 Year:+39.60%
6 Months:+53.19%
3 Months:+18.18%
1 Month:+13.80%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 98% of range
₹550.47 ₹1,001.90
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.45 · Neutral
Price Performance
1M+13.80%
3M+18.18%
6M+53.19%
1Y+39.60%
Valuation vs Sector

P/E of 67.33 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 32.4% over 5 years.
  • Profit CAGR of 38.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 67.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
67.33
Industry PE
41.64
Forward P/E
30.36
PEG Ratio
-
Book Value
₹184.79
Price to Book
4.71
P/S
6.80
EV/EBITDA
26.48
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
32.39%
Profit 5Y
38.67%
Revenue (YoY)
36.31%
Earnings (YoY)
34.34%

Profitability & Returns

ROCE
10.97%
ROE
9.85%
ROA
7.69%
Profit Margin
14.53%
Op Margin
16.92%
Gross Margin
61.14%
EPS (Latest Qtr)
₹4.93
EPS (TTM)
₹14.72

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
3.76
Current Ratio
3.87
Debt
₹264.09 Cr
Total Assets
₹2,281.53 Cr
Current Assets
₹712.02 Cr
Working Capital
₹528.13 Cr

Ownership

Promoter Holding
56.94%
Chg in Prom Hold
1.14%
FII / Inst Holding
12.49%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
₹9,549.68 Cr
Total Revenue (TTM)
₹1,207.17 Cr
EBITDA
₹317.90 Cr
Free Cash Flow
₹-112.02 Cr
Operating Cash Flow
₹204.52 Cr
Shares Outstanding
₹9.64 Cr
Gross Margin
61.14%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 YATHARTH Yatharth Hospital & Trauma Care Services Limited NSEPHARMA 991.10 67.33 ₹9,549.68 Cr 0.00% 10.97% 9.85% 32.39% 38.67%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 144.00 Cr155.00 Cr171.00 Cr167.00 Cr178.00 Cr212.00 Cr--233.03 Cr257.77 Cr279.42 Cr320.47 Cr341.56 Cr
Cost of Revenue --------88.21 Cr53.51 Cr56.40 Cr62.46 Cr132.28 Cr
Gross Profit --------144.82 Cr204.26 Cr223.02 Cr258.01 Cr209.29 Cr
Operating Expenses 105.00 Cr113.00 Cr126.00 Cr120.00 Cr131.00 Cr158.00 Cr--99.41 Cr154.69 Cr177.43 Cr207.72 Cr159.37 Cr
Operating Income 30.00 Cr34.00 Cr39.00 Cr38.00 Cr39.00 Cr43.00 Cr--45.41 Cr49.57 Cr45.59 Cr50.29 Cr49.91 Cr
EBITDA 38.00 Cr41.00 Cr46.00 Cr46.00 Cr47.00 Cr54.00 Cr--62.37 Cr73.80 Cr74.01 Cr82.07 Cr87.02 Cr
Interest Expense 6.00 Cr6.00 Cr3.00 Cr003.00 Cr--97.20 L19.00 L25.70 L1.02 Cr5.07 Cr
Pretax Income 25.00 Cr29.00 Cr40.00 Cr44.00 Cr44.00 Cr43.00 Cr--48.53 Cr58.69 Cr54.82 Cr57.10 Cr51.95 Cr
Tax Provision 7.75 Cr10.15 Cr12.00 Cr14.52 Cr5.72 Cr12.47 Cr--9.81 Cr16.65 Cr13.57 Cr14.01 Cr7.25 Cr
Net Income 17.00 Cr19.00 Cr28.00 Cr29.00 Cr38.00 Cr30.00 Cr--38.72 Cr42.04 Cr41.24 Cr45.35 Cr47.52 Cr
Diluted EPS 2.642.913.213.444.473.54--4.374.364.284.714.93

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 71.00 Cr78.00 Cr91.00 Cr136.00 Cr215.00 Cr-520.29 Cr670.55 Cr885.62 Cr1,207.17 Cr
Cost of Revenue ------92.94 Cr133.31 Cr338.92 Cr469.15 Cr
Gross Profit ------427.36 Cr537.24 Cr546.70 Cr738.02 Cr
Operating Expenses 53.00 Cr60.00 Cr71.00 Cr98.00 Cr147.00 Cr-319.70 Cr384.53 Cr378.49 Cr533.71 Cr
Operating Income 11.00 Cr12.00 Cr12.00 Cr17.00 Cr47.00 Cr-107.65 Cr152.70 Cr168.21 Cr204.31 Cr
EBITDA 18.00 Cr18.00 Cr20.00 Cr38.00 Cr68.00 Cr-136.57 Cr195.55 Cr236.42 Cr317.90 Cr
Interest Expense 6.00 Cr5.00 Cr7.00 Cr20.00 Cr20.00 Cr-21.39 Cr9.42 Cr7.51 Cr6.54 Cr
Pretax Income 5.00 Cr8.00 Cr5.00 Cr-2.00 Cr28.00 Cr-87.68 Cr156.83 Cr171.74 Cr223.56 Cr
Tax Provision 2.05 Cr1.84 Cr1.05 Cr36.00 L8.40 Cr-21.91 Cr42.36 Cr41.19 Cr53.26 Cr
Net Income 3.00 Cr6.00 Cr4.00 Cr-2.00 Cr20.00 Cr-65.77 Cr114.47 Cr130.54 Cr175.38 Cr
Diluted EPS 2.213.752.43-0.7911.095.147.6614.4614.72-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 138.00 Cr193.00 Cr257.00 Cr287.00 Cr309.00 Cr-485.97 Cr1,019.33 Cr1,731.18 Cr2,281.53 Cr
Current Assets ------176.27 Cr510.25 Cr855.73 Cr712.02 Cr
Cash & Equivalents ------37.23 Cr81.40 Cr204.96 Cr221.10 Cr
Inventory ------6.07 Cr8.13 Cr20.95 Cr20.67 Cr
Receivables ------107.64 Cr227.00 Cr301.50 Cr374.80 Cr
Total Liabilities ------303.00 Cr145.01 Cr94.05 Cr474.37 Cr
Current Liabilities ------99.52 Cr67.22 Cr84.58 Cr183.88 Cr
Long Term Debt ------200.59 Cr75.25 Cr96.90 L226.87 Cr
Total Debt 85.00 Cr125.00 Cr175.00 Cr194.00 Cr193.00 Cr-267.41 Cr84.65 Cr11.59 Cr264.09 Cr
Total Equity 43.00 Cr57.00 Cr55.00 Cr54.00 Cr72.00 Cr-182.96 Cr874.32 Cr1,605.46 Cr1,780.56 Cr
Shares Outstanding ------8.59 Cr8.59 Cr9.64 Cr9.64 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 25.00 Cr17.00 Cr17.00 Cr39.00 Cr44.00 Cr-63.78 Cr-3.08 Cr131.17 Cr204.52 Cr
Investing Cash Flow -50.00 Cr-51.00 Cr-78.00 Cr-43.00 Cr-21.00 Cr--20.31 Cr-225.87 Cr-387.58 Cr-598.03 Cr
Financing Cash Flow 26.00 Cr43.00 Cr47.00 Cr5.00 Cr-19.00 Cr--17.75 Cr304.21 Cr509.09 Cr253.53 Cr
Capital Expenditure -1.00 Cr-1.00 Cr-77.00 Cr-43.00 Cr-20.00 Cr--19.81 Cr-93.36 Cr-301.93 Cr-316.54 Cr
Free Cash Flow 24.00 Cr16.00 Cr-60.00 Cr-4.00 Cr24.00 Cr-43.97 Cr-96.44 Cr-170.75 Cr-112.02 Cr
Net Change in Cash 1.00 Cr9.00 Cr-13.00 Cr1.00 Cr3.00 Cr-25.73 Cr75.26 Cr252.69 Cr-139.98 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------82.1%80.1%61.7%61.1%
Operating Margin % 15.5%15.4%13.2%12.5%21.9%-20.7%22.8%19.0%16.9%
Net Margin % 4.2%7.7%4.4%-1.5%9.3%-12.6%17.1%14.7%14.5%
ROE % 7.0%10.5%7.3%-3.7%27.8%-35.9%13.1%8.1%9.8%
ROCE % ------27.9%16.0%10.2%9.7%

Shareholding Pattern

Insiders
56.94%
Institutions
12.49%
Public Float
29.01%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for YATHARTH

Google News Sat, 08 Aug 2026

Is It Too Late To Consider Buying Yatharth Hospital & Trauma Care Services Limited (NSE:YATHARTH)? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQWUtNdTZyM19FbzY5ZGZka0ZqWWJKamlOTWdMWVVoT0xsUFpXSkxnbjRFREY0TlhYeUJ6MzJQNDdJUUdUeENpaG9TNjFvSkl3bkJ5QTl1aDEtZFlTR2FrU096WUVqbVRpdDA5b0RPM0YxdWpEdDBTS1dyYmVUTWNyZkZZSWNTeHhQdjQxcl…

Google News Fri, 28 Aug 2026

Yatharth Hospitals draws interest from Aster, Advent as healthcare consolidation heats up - The Economic Times

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxNeHdLYklRbzdFZ2g2N2ZTSktSMEdtRXVETVAyX3BDaGFPODJEQXpMc3Naa3FnX1lzZFdNT0tXaHhZTG5zNDhQd0ZuM214aXNyY1VvMGpUVGtkVG43QjNaOEtRU3A2Z1l1eXBOVno0NDBJb3ZMTXhtdHJ2TVdENzB1aFViNDFQT293YjV3Ym…

Google News Fri, 28 Aug 2026

Aster, Advent eye controlling stake in Yatharth Hospital, says report; shares rise 4.5% - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNVHgybXYwYzBlT1RSZXZkZUg3cnIyd2R0RkR3UnRPQk1nXzc5UUgzNjd3V0dfbGloN0s2REJmcmx5NGsxSlNYbjBUcHg4NjdSS1Ixd1BjMDZ0aG01dlRQclFoQ1NBT2xGYUo1eTNDOGg0TWhmUndyZjdKQzhhWWVqRFI5a0tXbTQwVkhGMj…

Google News Fri, 04 Sep 2026

Yatharth Hospital files Business Responsibility and Sustainability Report for FY26 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPWWo2QnN5dGVxeTlNcUs1ZXFDUHphRHVpLTdOQXVfMFNENEFrMWhkTEhyV2J4Q1ZFQURCRDhpdTNKb0U3MG9YY2tiVnlPVEQ2aTNnbGpSTUMwSEhpeVpiQnFjR1RZMEtvSjA2YkxXT1J0dzdGSlpCb0lrNDFEUG1UdDNGNlZha05hc1RqS0…

Google News Fri, 28 Aug 2026

Yatharth Hospital gains 6% to new high as Aster, Advent eye majority stake - Business Standard

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPLUZvTmdqVnVfLUU0Z1BLMU9iQ1Bzdzd3TkM0bUM4d0J4V25UVHRacVR1RjE5QVNqY0hDaFptLWJ2X3JJcWpVOTNMVk16N2U3NWd2emYwQ0piLU40MVZmNzdoS0pfVWM1Z1hDcWFQSHU4OFdiT1d0YXViRDkzZFlhRC11MnRXRWt1ZFpsWl…

Google News Mon, 10 Aug 2026

Yatharth Hospital Q1 Results: Revenue Jumps 52%, Profit Grows 12% Even As Margins Narrow - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNWGpXNEF3bnp3T1RTNGZOZlQ3N1hyVU5zQXVxYk1kNU5KYURWbmNtZWJzSFNMSm1lNFhhZ3dZcHMzTkFBb1FNWlUyM2pBdXRud2dsWi1XUE1kdDc4ckhYdFJWazlNTVVrSWswSHpQb0EwV29RSm5ya1dJSzN5eWxjQUlaSUsybHhMMzQyR3…

YATHARTH — Frequently Asked Questions

What is the current share price of Yatharth Hospital & Trauma Care Services Limited (YATHARTH)?

As of 2026-09-08 04:53 IST, Yatharth Hospital & Trauma Care Services Limited (YATHARTH) trades at ₹991.10 on NSE. Its 52-week range is ₹550.47 to ₹1,001.90.

What is the market capitalisation of YATHARTH?

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) has a market capitalisation of ₹9,549.68 Cr on NSE.

What is the P/E ratio of YATHARTH?

YATHARTH trades at a trailing price-to-earnings (P/E) ratio of 67.33. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 4.71.

What is the return on equity (ROE) of YATHARTH?

YATHARTH has a return on equity (ROE) of 9.85%. Its return on capital employed (ROCE) is 10.97%.

Is YATHARTH a good stock to buy?

This page provides a data-driven analysis of Yatharth Hospital & Trauma Care Services Limited (YATHARTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space